Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%

Follow MRNA

Alert me

Market cap: $94.4B
P/E: 0.0×
Fwd P/E: −5.5×
Dividend yield: —
F-score: 3/9
Altman Z: 2.46
Beneish M: −3.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. 8-K filed Jul 8, 2026

Period ended Jul 6, 2026 · Filed Jul 8, 2026 · accepted 7:08 AM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Red flags

Officer departure Jul 8, 2026
Moderna, Inc. reported the departure of an officer or director

8-K filed Jul 8, 2026 · The filing · sec.gov

Moderna, Inc. 8-K filed Jul 8, 2026

Red flags

Stockrow Weekly